{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-004505","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.187484+00:00","generated_at":"2026-05-26T08:07:35.158428+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Omeros reports robust narsoplimab EAP survival data in TA-TMA; BLA resubmission planned Q1 2025","bullets":["Combined EAP + pivotal trial vs external control: HR 0.34-0.46, p-values <0.00001 to 0.00002.","Previously untreated high-risk adults: 1-year survival 58%; children: 79% in EAP.","Refractory patients (failed complement inhibitors): 1-year survival 44% vs historical <20%.","No safety signals; BLA resubmission expected later Q1 2025, MAA submission by mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-004505","json":"https://secwatch.observer/filing/0001437749-25-004505.json","markdown":"https://secwatch.observer/filing/0001437749-25-004505.md","text":"https://secwatch.observer/filing/0001437749-25-004505.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000143774925004505/0001437749-25-004505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000143774925004505/omer20250212_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T08:07:35.158428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}